肝细胞癌二线治疗的现状和进展
Current status and progress of second-line treatment for hepatocellular carcinoma
邓娜 1栗晓咪 1丁晓燕 1陈京龙1
作者信息
- 1. 首都医科大学附属北京地坛医院 肿瘤内科,北京 100015
- 折叠
摘要
目前晚期肝细胞癌(hepatocellular carcinoma,HCC)的治疗手段主要包括分子靶向治疗、免疫治疗和系统化疗等.晚期HCC的一线治疗手段包括以索拉非尼、仑伐替尼等为代表的分子靶向治疗以及以阿替利珠单抗、信迪利单抗等为代表的免疫治疗.无论是分子靶向治疗还是免疫治疗,由于缺乏特异性的靶点标志物,其治疗效果都有限,且进展及复发率高,因此晚期HCC的后线治疗显得尤为必要.本文就晚期HCC二线治疗的现状及进展进行综述.
Abstract
At present,the treatment of advanced hepatocellular carcinoma(HCC)mainly includes molecular targeted therapy,immunotherapy and systemic chemotherapy.The first-line systemic regimens of advanced HCC include molecular targeted therapy represented by sorafenib and lenvatinib,and immunotherapy represented by atelizumab and sintilimab.Whether molecular targeted therapy or immunotherapy,due to the lack of specific biomarkers,the efficacy is limited,and the rate of progression and recurrence is high,so the post-line treatment of advanced HCC is particularly necessary.This article reviewed the current status and progress of second-line treatment for advanced HCC.
关键词
肝细胞癌/靶向治疗/免疫治疗/二线治疗Key words
Hepatocellular carcinoma/Targeted therapy/Immunotherapy/Second-line therapy引用本文复制引用
基金项目
首都卫生发展科研专项(2022-2-2175)
出版年
2024
NETL
NSTL
万方数据